 CytoDyn Inc OTCQB:CYDY announced that the scientific journal Nature Communications published a study showing that leronlimab prevented nonhuman primates from being infected with Simian Human Immunodeficiency virus SHIV, a monkey-human chimeric form of HIV. The results will inform a future human clinical trial evaluating leronlimab as a potential pre-exposure prophylaxis, or PrEP, therapy to prevent human infection from the virus that causes AIDS, the company said. 